Univercells partners with Takeda to produce affordable vaccines for developing countries

Belgium-based Univercells says it has closed an equity investment of 3 million euros ($3.3million) with Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) through its strategic venture arm, Takeda Ventures Inc.

The companies will launch a development program to tailor Univercells’ continuous integrated manufacturing methods and integrate them into the Takeda vaccines production platform, aiming to produce affordable vaccines for developing countries.

“Partnering with Takeda is a strong sign we are heading in the right direction. We are excited to collaborate with a pioneering global player focused on helping people above all else,” said Hugues Bultot, chief executive of Univercells.